PCSK9 Inhibitor well tolerated in patients with statin intolerance
Patients with self-reported statin intolerance may benefit from proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, which have been shown to lower atherogenic lipid markers in this population, suggests a recent study.